Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leading innovator in advanced wound care solutions, today announced that its subsidiary, Resorbable Orthopedic Products, LLC, has entered into a Development and License Agreement with Newport Beach, CA-based BioStructures, LLC to develop products for bone remodeling in the human skeletal system based on ROP’s patent. BioStructures has paid ROP an initial $100K licensing fee and the agreement calls for ROP to receive additional license fees as well as royalties on sales throughout the life of the patent. Under this contract, minimum royalties will begin in 2013 and last until 2023. Initial commercial sales from this business are expected in 2013.
“This transaction allows us to combine our portfolio of proprietary biomaterials with a patented resorbable wax carrier. The combination of these products will further enhance the dynamic product lineup of BioStructures,” said Russell Cook, CEO of BioStructures, LLC.
“We are pleased to have reached a license agreement with BioStructures to develop many of the orthopedic products related to Resorbable Orthopedic Products’ patent on resorbable bone wax and bone void fillers. This agreement is the first commercial agreement for our subsidiary ROP and marks the start of a second product line for WNDM,” said Deborah Hutchinson, president of Wound Management Technologies. “We believe that BioStructures is the right partner to develop and market these important orthopedic products and we look forward to strong success of these products in the marketplace.”
ROP’s patent was developed by WNDM advisor Barry Constantine and his associates and was acquired by WNDM in 2009. Mr. Constantine will oversee ROP’s development responsibilities with BioStructures. “Commercialization of the BioStructures product containing the ROP technology in addition to the development and commercialization of other embodiments within the ROP patent advances the practice of orthopedic surgery,” said Barry Constantine. “We are excited to see our technology move into product development with BioStructures.”
Resorbable Orthopedic Products may commercialize additional products covered by the patent, including a resorbable orthopedic hemostat (resorbable bone wax), a resorbable orthopedic hemostat antimicrobial dressing and products for the veterinary market.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage. More information can be found on the company’s web sites: http://www.wmgtech.com and http://www.celleraterx.com.
About BioStructures
BioStructures is a company which designs and develops synthetic bone graft materials for orthopedic applications. Our platform is based on proprietary technologies and patented biomaterials that provide for unique mechanisms of action in the body and offer a breadth of products for the regeneration of human bone. The company has experienced strong commercial success in the United States with our OsteoMatrix Mineralized Collagen Scaffold and Interface Bioactive Bone Graft products. In addition, BioStructures has a robust pipeline of innovative bone graft products which are in various stages of development. For more information about BioStructures, please visit www.biostructures.net.
Safe Harbor Statement:
The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com